Epizyme, Inc.: management transactions · United States · SEC (Form 4)

About Epizyme, Inc.

Epizyme, Inc. was a U.S. biopharmaceutical company listed on the NASDAQ under ticker EPZM before being acquired by Ipsen, with the transaction completed in August 2022. Headquartered in Cambridge, Massachusetts, United States, the company began active operations in 2008 and focused on the discovery, development, and commercialization of epigenetic medicines for oncology. Its strategy was built around a research platform designed to address specific biological drivers of hematologic malignancies and selected solid tumors. Epizyme’s lead and most commercially important asset was TAZVERIK (tazemetostat), an oral EZH2 inhibitor. The drug received FDA accelerated approval in January 2020 for epithelioid sarcoma and in June 2020 for follicular lymphoma, establishing the company as a specialized player in rare-cancer targeted therapies. TAZVERIK was central to Epizyme’s revenue generation and investor story, and the company positioned the medicine as a differentiated, chemotherapy-free option in settings with limited treatment choices. Beyond the marketed product, Epizyme also had development programs including EZM0414, an oral SETD2 inhibitor, plus additional preclinical epigenetic programs. From a competitive standpoint, Epizyme operated in a highly demanding segment of biotech where clinical validation, regulatory execution, and physician adoption are critical. Its market position was that of a small-cap innovation company rather than a diversified oncology franchise, which made the business highly dependent on the success of a single commercial asset and a narrow pipeline. Commercial launch of TAZVERIK in the United States started in 2020, but the company remained exposed to concentration risk and the need to extend the label and broaden usage. Geographically, Epizyme was primarily U.S.-focused, though it had historically pursued select international collaboration arrangements. A major recent development was the definitive merger agreement announced in June 2022 and the closing of Ipsen’s acquisition in August 2022, after which EPZM ceased to trade as an independent NASDAQ-listed equity. For French-speaking and international investors, Epizyme is best viewed as a classic oncology biotech story: a science-driven company with one approved product, a focused pipeline, and a value path ultimately shaped by M&A rather than long-term standalone scale.